ATLANTA, GA – – (Businesswire – August 1, 2017) – – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased IntelliPharmaCeutics International, Inc. (“IntelliPharmaCeutics” or the “Company”) (NASDAQ: IPCI) common stock between January 14, 2016 and July 26, 2017. The case alleges that the Company and certain of its executive officers made false and misleading statements during that time. Specifically, the Complaint alleges the Company failed to submit sufficient evidence to the FDA to support its New Drug Application for its main product candidate, Rexista. On July 27, 2017, the Company’s stock price declined significantly following the FDA’s announcement that “the safety information collected in the pharmacokinetic studies [for Rexista] was of limited value.” If you purchased IntelliPharmaCeutics common stock between January 14, 2016 and July 26, 2017 and suffered losses on that investment, you are encouraged to visit the firm’s website at www.holzerlaw.com to receive additional information about your legal rights. You can also contact Corey D. Holzer, Esq. at email@example.com or Alexandria P. Rankin, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832 for more information. The case is pending in the United States District Court for the Southern District of New York and the deadline to move for appointment as lead plaintiff is September 29, 2017.